Summit Global Investments Decreases Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Summit Global Investments reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,506 shares of the specialty pharmaceutical company’s stock after selling 198 shares during the quarter. Summit Global Investments owned approximately 0.09% of ANI Pharmaceuticals worth $1,078,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ANIP. Victory Capital Management Inc. lifted its stake in shares of ANI Pharmaceuticals by 153.6% during the 3rd quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock worth $771,000 after purchasing an additional 7,825 shares during the last quarter. Natixis Advisors LLC lifted its stake in shares of ANI Pharmaceuticals by 56.2% during the 3rd quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock worth $1,085,000 after purchasing an additional 6,545 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares during the last quarter. Quest Partners LLC increased its position in ANI Pharmaceuticals by 141.1% during the 3rd quarter. Quest Partners LLC now owns 9,893 shares of the specialty pharmaceutical company’s stock valued at $590,000 after buying an additional 5,789 shares in the last quarter. Finally, Segall Bryant & Hamill LLC increased its position in ANI Pharmaceuticals by 1.7% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 44,872 shares of the specialty pharmaceutical company’s stock valued at $2,677,000 after buying an additional 740 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ANIP. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 target price on the stock. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price on the stock. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 14th. Finally, Guggenheim upped their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.75.

Insider Activity

In related news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company’s stock, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,200 shares of company stock valued at $191,776. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.1 %

Shares of ANIP stock opened at $64.26 on Friday. The stock’s 50-day simple moving average is $59.39 and its 200-day simple moving average is $58.13. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market capitalization of $1.40 billion, a PE ratio of -116.84 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.